Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities

v3.22.1
Accrued Expenses and Other Liabilities
 3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued Expenses, summarized by major category, as of March 31, 2022 and December 31, 2021 consist of the following:

 

    March 31, 2022     December 31, 2021  
Payroll and incentives   $ 482     $ 1,343  
General and administrative expenses     302       195  
Research and development expenses     355       381  
Deferred revenue and other deferred liabilities *     702       932  
Total   $ 1,841     $ 2,851  

 

* At March 31, 2022, approximately $669 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech Agreement. At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement.